Our core team to cover what this platform demands: RNA biology, delivery science, computational discovery, drug development and business execution.
Leads SRTD through its transition from platform research to clinical development.
Thirty years as a biotech executive in the US and Europe, with prior roles at Autolus, GAIN Therapeutics, Cytos, Sucampo, Micromet and Novartis.
Inventor of the seRNA construct and of the fusogenic LNP delivery platform.
Group leader at Forschungszentrum Jülich, author of more than 100 publications, various patents and founder of three companies.
Runs target discovery and AI-driven seRNA optimization.
Professor at TU Darmstadt working on bioinformatics and AI, with more than 170 publications and five patents.
Leads partnering and corporate development.
Managing Director of HBCD Advisors, previously in biotech executive roles at SOTIO and Micromet, and board roles at NBE Therapeutics, Cytune Pharma and Athebio.
Merieux Equity Partners
NRW Ventures
High-Tech Gründerfonds Management GmbH
Boehringer Ingelheim Venture Funds
CEO, SRTD Biotech